A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Temozolomide (Primary) ; Vitespen (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 25 Jul 2024 Status changed from completed to discontinued.
- 21 Dec 2022 Status changed from active, no longer recruiting to completed.
- 30 Sep 2021 Status changed from recruiting to active, no longer recruiting.